A Graphene Oxide-Functionalized Fiber Optic Biosensor for Breast Cancer Biomarker Detection: Toward Developing a Highly Sensitive Multi-Fluid Diagnostic Platform.
Graphene oxide-coated semi-distributed interferometric biosensor is established as a highly sensitive platform for CD44 detection in clinically relevant samples and its potential for future development toward the detection of other circulating biomarkers is highlighted.
Abstract
Tumor cells release biomarkers, such as CD44, into circulation, offering a minimally invasive window into tumor biology. However, conventional analytical methods often lack the sensitivity and dynamic range needed to detect these markers reliably in complex biological samples. Here, we exploit graphene oxide-coated semi-distributed interferometry to fabricate an optical fiber biosensor for sensitive CD44 detection. To establish the proof-of-concept, we focus on CD44 because of its well-established role as a circulating biomarker in breast cancer. We functionalize the sensor surface with anti-CD44 antibodies, confirm successful biofunctionalization and antibody specificity through complementary surface characterization and immunological assays, and optimize the platform to achieve a wide dynamic range and a limit of detection of 175 aM. Validation using clinical serum samples from breast cancer patients demonstrated a higher signal for cancer patients than for the healthy group, while successful detection of soluble CD44 in urine further demonstrated the biosensor's compatibility with multiple biological matrices. These findings establish the graphene oxide-coated semi-distributed interferometric biosensor as a highly sensitive platform for CD44 detection in clinically relevant samples. The demonstrated performance, together with the adaptability of the underlying SDI sensing architecture, highlights its potential for future development toward the detection of other circulating biomarkers.
The development of a graphene oxide-coated fiber-optic biosensor based on a semi-distributed interferometric sensing platform for the highly sensitive detection of solCD44, a cell adhesion glycoprotein whose soluble form is elevated in several cancers including breast cancer, is reported.
K. Seitkamal, A. Bekmurzayeva, A. Aubakirova et al.· Oncology, Nuclear Medicine a...· 0 citations
Results support the potential of the antibody-functionalized ESDI platform for label-free detection of CD44-expressing cells, providing a groundwork for its validation in clinical samples as a step toward tumor-cell diagnostics.
Osteosarcoma is a malignant bone tumor for which diagnosis is critical to patient prognosis. MicroRNA-588 is downregulated in osteosarcoma, highlighting its potential as a diagnostic biomarker. However, its low abundance in body fluids makes sensitive detection difficult. This study presents a label-free reflective opt...
Xiao-Han Chen, Peng Song, Yi-Hao Wang et al.· Advanced Healthcare Material...· 0 citations
The developed fiber-optic biosensors show potential for integration into liquid biopsy platforms for label-free detection of circulating tumor cells in biological fluids, providing a rapid and minimally invasive approach for cancer detection and monitoring.
Aigerim Omirzakova, Lyazzat Mukhangaliyeva, Marzhan Nurlankyzy et al.· Oncology, Nuclear Medicine a...· 0 citations